Cardiometabolic comorbidities and life expectancy in people on medication for schizophrenia in Australia

References

• Laursen TM. Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophrenia Res 2011;131:101-4
   PubMed Web of Science ®Google Scholar
• Laursen TM, Wahlbeck K, Hallgren J, et al. Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries. PLoS One 2013;8:e67133
   PubMed Web of Science ®Google Scholar
• Hjor Thor C, Sturup AE, McGrath JJ, et al. Years of life lost and expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry 2017;4:295-301
   PubMed Web of Science ®Google Scholar
• Brown S, Kim M, Mitchell C, et al. Twenty five year mortality of a community cohort with schizophrenia. Br J Psychiatry 2010;196:116-21
   PubMed Web of Science ®Google Scholar
• Olfson M, Gerhard T, Huang C, et al. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry 2015;1737:E1-E10
   Google Scholar
• Crump C, Winkleby MA, Sundquist K, et al. Comorbidities and mortality in persons with schizophrenia: a Swedish National Cohort Study. Am J Psychiatry 2013;270:324-33
   Web of Science ®Google Scholar
• Nielsen RE, Uggerby AS, Jensen SO, et al. Increasing mortality gap for patients diagnosed with schizophrenia over the last three decades—a Danish nationwide study from 1980 to 2010. Schizophrenia Res 2013;146:22-7
   PubMed Web of Science ®Google Scholar
• Laursen TM, Nordentoft M. Heart disease treatment and mortality in schizophrenia and bipolar disorder—changes in the Danish population between 1994 and 2006. J Psychiatric Res 2011;45:29-35
   PubMed Web of Science ®Google Scholar
• Galletly CA, Foley DL, Waterreus A, et al. Cardiometabolic risk factors in people with psychotic disorders: the second Australian national survey of psychosis. Aust NZ J Psychiatry 2012;46:753-61
   PubMed Web of Science ®Google Scholar
• Morgan V, Waterreus A, Jablensky A, et al. People living with psychotic illness in 2010: the second Australian national survey of psychosis. Aust NZ J Psychiatry 2012;46:735-52
   PubMed Web of Science ®Google Scholar
• Morgan VA, McGrath JJ, Jablensky A, et al. Psychosis prevalence and physical, metabolic and cognitive co-morbidity: data from the second Australian national survey of psychosis. Psychol Med 2014;44:2163-76
   PubMed Web of Science ®Google Scholar
• Cooper J, Mancuso SG, Borland R, et al. Tobacco smoking among people living with a psychotic illness: the second Australian Survey of Psychosis. Aust NZ J Psychiatry 2012;46:851-63
   PubMed Web of Science ®Google Scholar
• De Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophrenia Res 2005;76:135-57
   PubMed Web of Science ®Google Scholar
• Dipasquale S, Pariante CM, Dazzan P, et al. The dietary pattern of patients with schizophrenia: a systematic review. J Psychiat Res 2013;47:197-207
   PubMed Web of Science ®Google Scholar
• Hahn LA, Galletly CA, Foley DL, et al. Inadequate fruit and vegetable intake in people with psychosis. Aust NZ J Psychiatry 2014;48:1025-35
   PubMed Web of Science ®Google Scholar
• Roick C, Fritz-Wieacker AF, Matschinger H. Health habits of patients with schizophrenia: a general pattern? Soc Psychiatry Psychiat Epidemiol 2007;42:268-76
   PubMed Web of Science ®Google Scholar
• Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract 2014;943162. doi:10.1155/2014/943162
   PubMedGoogle Scholar
• Heiskanen T, Niskanen L, Lyytikainen R, et al. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003;64:575-9
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Res 2005;80:19-32.
   PubMed Web of Science ®Google Scholar
• Saari KM, Lindeman SM, Viilo KM, et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. J Clin Psychiatry 2005;66:559-63
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007;68(Suppl 4):8-13
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Lonnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009;374:620-7
   PubMed Web of Science ®Google Scholar
• Tornianen M, Mittendorfer-Rutz E, Tanskanen A, et al. Antipsychotic treatment and mortality in schizophrenia. Schizophrenia Bull 2015;41:656-63
   PubMed Web of Science ®Google Scholar
• Schoepf D, Uppal H, Potluri R, et al. Physical comorbidity and its relevance on mortality in schizophrenia: a naturalistic 12-year follow-up in general hospital admissions. Eur Arch Psychiatry Clin Neurosci 2014;264:3-28
   PubMed Web of Science ®Google Scholar
• Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Ann Rev Clin Psychol 2014;10:425-48
   PubMed Web of Science ®Google Scholar
• Kritharides L, Chow V, Lambert JR. Cardiovascular disease in patients with schizophrenia. Med J Aust 2017;206:91-5
   PubMed Web of Science ®Google Scholar
• De Hert M, Cohen D, Bobes J, et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. W Psychiatry 2011;10:138-51
   PubMed Web of Science ®Google Scholar
• Mackell JA, Harrison DJ, McDonnell DD. Relationship between preventative physical health care and mental health in individuals with schizophrenia: a survey of caregivers. Mental Health Serv Res 2005;7:225-8
   PubMedGoogle Scholar
• Mitchell AJ, Delaffon V, Vancampfort D, et al. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med 2012;42:125-47
   PubMed Web of Science ®Google Scholar
• Smith DJ, Langan J, McLean G, et al. Schizophrenia is associated with excess multiple physical-health comorbidities but low levels of recorded cardiovascular disease in primary care: cross-sectional study. BMJ Open 2013;3:e002808
   PubMed Web of Science ®Google Scholar
• Waterreus A, Morgan V, Castle D, et al. Medication for psychosis: consumption and consequences: the second Australian national survey of psychosis. Aust NZ J Psychiatry 2012;46:762-73
   PubMed Web of Science ®Google Scholar